Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State
The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit?In his new work, Priv...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Toronto
University of Toronto Press
[2018]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAB01 FCO01 FHA01 FKE01 FLA01 UPA01 Volltext |
| Zusammenfassung: | The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies' quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public's favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years |
| Beschreibung: | Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021) |
| Beschreibung: | 1 online resource (384 pages) 6 figures |
| ISBN: | 9781442619609 |
| DOI: | 10.3138/9781442619609 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV048364182 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220718s2018 |||| o||u| ||||||eng d | ||
| 020 | |a 9781442619609 |9 978-1-4426-1960-9 | ||
| 024 | 7 | |a 10.3138/9781442619609 |2 doi | |
| 035 | |a (ZDB-23-DGG)9781442619609 | ||
| 035 | |a (OCoLC)1337120339 | ||
| 035 | |a (DE-599)BVBBV048364182 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1043 |a DE-1046 |a DE-858 |a DE-Aug4 |a DE-859 |a DE-860 |a DE-739 | ||
| 082 | 0 | |a 338.4/761510971 |2 23 | |
| 100 | 1 | |a Lexchin, Joel |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Private Profits versus Public Policy |b The Pharmaceutical Industry and the Canadian State |c Joel Lexchin |
| 264 | 1 | |a Toronto |b University of Toronto Press |c [2018] | |
| 264 | 4 | |c © 2016 | |
| 300 | |a 1 online resource (384 pages) |b 6 figures | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021) | ||
| 520 | |a The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies' quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public's favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years | ||
| 546 | |a In English | ||
| 650 | 7 | |a HEALTH & FITNESS / Health Care Issues |2 bisacsh | |
| 650 | 4 | |a Drug development |x Government policy |z Canada | |
| 650 | 4 | |a Pharmaceutical industry |x Government policy |z Canada | |
| 650 | 4 | |a Prescription pricing |x Government policy |z Canada | |
| 650 | 4 | |a Profit |x Government policy |z Canada | |
| 856 | 4 | 0 | |u https://doi.org/10.3138/9781442619609 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-23-DGG | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033743321 | ||
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FAW01 |p ZDB-23-DGG |q FAW_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FAB01 |p ZDB-23-DGG |q FAB_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FCO01 |p ZDB-23-DGG |q FCO_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FHA01 |p ZDB-23-DGG |q FHA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FKE01 |p ZDB-23-DGG |q FKE_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l FLA01 |p ZDB-23-DGG |q FLA_PDA_DGG |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.3138/9781442619609 |l UPA01 |p ZDB-23-DGG |q UPA_PDA_DGG |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804184230402457600 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Lexchin, Joel |
| author_facet | Lexchin, Joel |
| author_role | aut |
| author_sort | Lexchin, Joel |
| author_variant | j l jl |
| building | Verbundindex |
| bvnumber | BV048364182 |
| collection | ZDB-23-DGG |
| ctrlnum | (ZDB-23-DGG)9781442619609 (OCoLC)1337120339 (DE-599)BVBBV048364182 |
| dewey-full | 338.4/761510971 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/761510971 |
| dewey-search | 338.4/761510971 |
| dewey-sort | 3338.4 9761510971 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.3138/9781442619609 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03307nmm a2200505zc 4500</leader><controlfield tag="001">BV048364182</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220718s2018 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781442619609</subfield><subfield code="9">978-1-4426-1960-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3138/9781442619609</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-23-DGG)9781442619609</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1337120339</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048364182</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1043</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-858</subfield><subfield code="a">DE-Aug4</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/761510971</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lexchin, Joel</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Private Profits versus Public Policy</subfield><subfield code="b">The Pharmaceutical Industry and the Canadian State</subfield><subfield code="c">Joel Lexchin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Toronto</subfield><subfield code="b">University of Toronto Press</subfield><subfield code="c">[2018]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (384 pages)</subfield><subfield code="b">6 figures</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies' quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public's favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Health Care Issues</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prescription pricing</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Profit</subfield><subfield code="x">Government policy</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033743321</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAW_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FAB01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAB_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FCO01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FCO_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FHA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FHA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FKE01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FKE_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">FLA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FLA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.3138/9781442619609</subfield><subfield code="l">UPA01</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UPA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV048364182 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:15:15Z |
| indexdate | 2024-07-10T09:36:02Z |
| institution | BVB |
| isbn | 9781442619609 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033743321 |
| oclc_num | 1337120339 |
| open_access_boolean | |
| owner | DE-1043 DE-1046 DE-858 DE-Aug4 DE-859 DE-860 DE-739 |
| owner_facet | DE-1043 DE-1046 DE-858 DE-Aug4 DE-859 DE-860 DE-739 |
| physical | 1 online resource (384 pages) 6 figures |
| psigel | ZDB-23-DGG ZDB-23-DGG FAW_PDA_DGG ZDB-23-DGG FAB_PDA_DGG ZDB-23-DGG FCO_PDA_DGG ZDB-23-DGG FHA_PDA_DGG ZDB-23-DGG FKE_PDA_DGG ZDB-23-DGG FLA_PDA_DGG ZDB-23-DGG UPA_PDA_DGG |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | University of Toronto Press |
| record_format | marc |
| spelling | Lexchin, Joel Verfasser aut Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State Joel Lexchin Toronto University of Toronto Press [2018] © 2016 1 online resource (384 pages) 6 figures txt rdacontent c rdamedia cr rdacarrier Description based on online resource; title from PDF title page (publisher's Web site, viewed 24. Aug 2021) The widespread condemnation of drastic price increases on life-saving drugs highlights our growing dependency on and vulnerability to international pharmaceutical conglomerates. However, aren't the interests of the public supposed to supersede the pursuit of private profit?In his new work, Private Profits versus Public Policy, Joel Lexchin addresses this question as he examines how public policy with respect to the pharmaceutical industry has evolved in Canada over the past half century. Although the Canadian government is supposed to regulate the industry to serve the needs of public health, waves of deregulatory reforms and intellectual property rights legislation have shifted the balance of power in favour of these companies' quest for profit. Joel Lexchin offers a series of recommendations to tip the scale back in the public's favour. This enlightening work is the first book that deals exclusively with the pharmaceutical industry in Canada in over thirty years In English HEALTH & FITNESS / Health Care Issues bisacsh Drug development Government policy Canada Pharmaceutical industry Government policy Canada Prescription pricing Government policy Canada Profit Government policy Canada https://doi.org/10.3138/9781442619609 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Lexchin, Joel Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State HEALTH & FITNESS / Health Care Issues bisacsh Drug development Government policy Canada Pharmaceutical industry Government policy Canada Prescription pricing Government policy Canada Profit Government policy Canada |
| title | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State |
| title_auth | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State |
| title_exact_search | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State |
| title_exact_search_txtP | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State |
| title_full | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State Joel Lexchin |
| title_fullStr | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State Joel Lexchin |
| title_full_unstemmed | Private Profits versus Public Policy The Pharmaceutical Industry and the Canadian State Joel Lexchin |
| title_short | Private Profits versus Public Policy |
| title_sort | private profits versus public policy the pharmaceutical industry and the canadian state |
| title_sub | The Pharmaceutical Industry and the Canadian State |
| topic | HEALTH & FITNESS / Health Care Issues bisacsh Drug development Government policy Canada Pharmaceutical industry Government policy Canada Prescription pricing Government policy Canada Profit Government policy Canada |
| topic_facet | HEALTH & FITNESS / Health Care Issues Drug development Government policy Canada Pharmaceutical industry Government policy Canada Prescription pricing Government policy Canada Profit Government policy Canada |
| url | https://doi.org/10.3138/9781442619609 |
| work_keys_str_mv | AT lexchinjoel privateprofitsversuspublicpolicythepharmaceuticalindustryandthecanadianstate |